January 26, 2024

Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules

January 22, 2024

Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002

January 02, 2024

Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024

December 22, 2023

Seelos Therapeutics, Inc. Releases Letter to its Stockholders

December 01, 2023

Seelos Therapeutics Announces Closing of Public Offering

November 28, 2023

Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering

November 28, 2023

Seelos Therapeutics Announces Proposed Public Offering

November 27, 2023

Seelos Therapeutics Announces the Selection of SLS-002 (intranasal racemic ketamine) for Inclusion in the U.S. Department of Defense's Adaptive Platform Trial to Evaluate Potential Treatments for Post-Traumatic Stress Disorder (PTSD)

November 24, 2023

Seelos Therapeutics Announces 1-for-30 Reverse Stock Split

October 27, 2023

Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023

October 17, 2023

Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations

September 27, 2023

Seelos Therapeutics Announces Encouraging Data from an In Vivo Study of SLS-005 in an Aggressive Preclinical Model of Alzheimer's Disease

September 21, 2023

Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

September 20, 2023

Seelos Therapeutics Announces Top Line Results from SLS-002 Phase II Study in Adults with Major Depressive Disorder at Imminent Risk of Suicide

August 14, 2023

Seelos Therapeutics Provides Second Quarter 2023 Clinical Update

June 22, 2023

Seelos Therapeutics Announces the Close of Enrollment of its Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in Adults with Major Depressive Disorder (MDD)

May 22, 2023

Seelos Therapeutics to Participate in Two Upcoming Healthcare Conferences

May 15, 2023

Seelos Therapeutics Provides Clinical Update and Reports First Quarter 2023 Financial Results

May 05, 2023

Seelos Therapeutics to Present a Poster on SLS-009 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

April 04, 2023

Seelos Therapeutics Doses the First Amyotrophic Lateral Sclerosis (ALS) Patient with SLS-005 in an Expanded Access Program

March 29, 2023

Seelos Therapeutics Announces Business Update on its Key Programs

March 10, 2023

Seelos Therapeutics Announces Registered Direct Offering of Common Stock and Warrants to Purchase Common Stock

February 15, 2023

Seelos Therapeutics to Participate in 43rd Annual Cowen Health Care Conference

February 13, 2023

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

February 10, 2023

Seelos Therapeutics to Present a Poster on SLS-004 at the 11th Annual Alzheimer's & Parkinson's Drug Development Summit

February 06, 2023

Seelos Therapeutics Doses First Patients in an Ethnobridging Study with SLS-002 (Intranasal Racemic Ketamine)

December 22, 2022

Seelos Therapeutics to Participate in the 12th Annual LifeSci Partners Corporate Access Event

December 15, 2022

Seelos Therapeutics Announces Data Demonstrating Downregulation of Alpha Synuclein in an In Vivo Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Parkinson's Disease

December 08, 2022

Seelos Therapeutics Releases the Itinerary for its Research and Development Update Conference Call and Webcast to be Held on December 15, 2022

November 23, 2022

Seelos Therapeutics to Hold a Research and Development Update Conference Call and Webcast on December 15, 2022

November 07, 2022

Seelos Therapeutics to Participate in the Guggenheim 4th Annual Immunology and Neurology Day

October 27, 2022

Seelos Therapeutics to Sponsor and Participate in Wonderland, the World's Leading Psychedelic Event

October 25, 2022

Seelos Therapeutics Doses First Patient in a Registrational Phase II/III study of SLS-005 in Spinocerebellar Ataxia

September 30, 2022

Seelos Therapeutics to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program Funded by a Grant from the National Institute of Neurological Disorders and Stroke under the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS)

September 13, 2022

Seelos Therapeutics Announces the Participation of Acadia Healthcare in the Registration Directed Study of SLS-002 (Intranasal Racemic Ketamine) for Acute Suicidal Ideation and Behavior in Patients with Major Depressive Disorder

September 09, 2022

Seelos Therapeutics to Participate in the Guggenheim Nantucket Therapeutics Conference

August 30, 2022

Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences

August 24, 2022

Seelos Therapeutics Receives a Research and Development Grant from The Michael J. Fox Foundation for Parkinson's Research for SLS-004

July 18, 2022

Seelos Therapeutics Doses First Patient in an Open Label Basket Study of SLS-005 in Amyotrophic Lateral Sclerosis in Australia and Provides an Enrollment Update of its Study on the HEALEY ALS Platform

June 09, 2022

Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies

May 18, 2022

Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007

May 12, 2022

Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

April 22, 2022

Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference

April 11, 2022

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee

March 08, 2022

Seelos Therapeutics Receives an Acknowledgement Letter of a Clinical Trial Notification from the Australian Government Department of Health Therapeutic Goods Administration for a Pilot Study of SLS-005 in Alzheimer's Disease

March 07, 2022

Seelos Therapeutics Announces Year-End 2021 Business and Clinical Update

February 28, 2022

Seelos Therapeutics Announces Dosing of the First Participants in a Registrational Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform

December 21, 2021

Seelos Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 16, 2021

Seelos Therapeutics to Participate in the 11th Annual LifeSci Partners Corporate Access Event

December 06, 2021

Seelos Therapeutics Announces Issuance of Composition of Matter Patent in Japan for SLS-007